ArticleJAMA internal medicine2020
Assessment of Lung Cancer Screening Program Websites.
Article in JAMA internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Supporting community translation of lung cancer screening: A web-based decision aid to support informed decision making.Translational behavioral medicine · 2025Trial
- Effect of Incidental Findings Information on Lung Cancer Screening Intent: a Randomized Controlled Trial.Journal of general internal medicine · 2022Trial
- The quality of patient decision aids for lung cancer screening: Results from an environmental scan.Cancer · 2025Review
- Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers: a cross sectional study.EClinicalMedicine · 2025Article
- Review
- A study protocol for a mixed-method environmental scan of contextual factors that influence lung cancer screening adherence.Implementation science communications · 2024Article
- Ethical Dimensions of Population-Based Lung Cancer Screening in Canada: Key Informant Qualitative Description Study.Public health ethics · 2024Article
- Development and validation of a tumor marker-based model for the prediction of lung cancer: an analysis of a multicenter retrospective study in Shanghai, China.Frontiers in oncology · 2024Article
- Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer.Cancers · 2023Review
- Opportunities and Challenges in Lung Cancer Screening Implementation: A Narrative Review.Current challenges in thoracic surgery · 2023Article
- Assessment of Lung Cancer Screening Eligibility on NCI-Designated Cancer Center Websites.Journal of cancer education : the official journal of the American Association for Cancer Education · 2022Review
- Assessing Information Available for Health Professionals and Potential Participants on Lung Cancer Screening Program Websites: Cross-sectional Study.JMIR cancer · 2022Article
- Prospective Multisite Cohort Study to Evaluate Shared Decision-Making Utilization Among Individuals Screened for Lung Cancer.Journal of the American College of Radiology : JACR · 2022Observational
- [Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Clinician and Patient Characteristics Associated With Lung Cancer Screening Following a Shared Decision-making Visit.JAMA network open · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The US Preventive Services Task Force recommends that individuals at high risk for lung cancer consider benefits and harms before pursuing lung cancer screening. Medical centers develop websites for their lung cancer screening programs, but to date little is known about the websites' portrayal of benefits and harms or what next steps they recommend for individuals considering screening. Objective: To assess the presentation of potential benefits and harms and recommended next steps on lung cancer screening program websites. Design, Setting, and Participants: Cross-sectional content analysis of 162 lung cancer screening program websites of academic medical centers (n = 81) and state-matched community medical centers (n = 81) that were randomly selected from American College of Radiology lung cancer screening-designated centers was conducted. The study was performed from December 1, 2018, to January 31, 2019. Main Outcomes and Measures: Website presentation of screening-associated benefits and harms was the primary outcome. Benefit was defined as any description related to the potential reduction in lung cancer mortality. Harms were based on the US Preventive Services Task Force recommendations and included false positives, false negatives, overdiagnosis, radiation exposure, and incidental findings. The secondary outcome was next steps that are recommended by websites. Results: Overall, the 162 lung cancer screening program websites described the potential benefits more frequently than they described any potential harms (159 [98%] vs 78 [48%], P < .01). False-positive findings were the most frequently reported (72 [44%]) potential harm. Community centers were less likely than academic centers to report any potential harm (32 [40%] vs 46 [57%], P = .03), potential harm from radiation (20 [25%] vs 35 [43%], P = .01), and overdiagnosis (0% vs 11 [14%], P < .01). One hundred nineteen websites (73%) did not explicitly recommend that individuals personally consider the potential benefits and harms of screening; community centers were less likely than academic centers to give this recommendation (15 [19%] vs 28 [35%], P = .02). Most institutions (157 [97%]) listed follow-up steps for screening, but few institutions (35 [22%]) recommended that individuals discuss benefits and harms with a health care professional. Conclusions and Relevance: Information on public-facing websites of US lung cancer screening programs appears to lack balance with respect to portrayal of potential benefits and harms of screening. Important harms, such as overdiagnosis, were commonly ignored in the sites evaluated, and most of the centers did not explicitly guide individuals toward a guideline-recommended, shared decision-making discussion of harms and benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.